Best Practice & Research Clinical Anaesthesiology
Volume 22, Issue 2 , Pages 369-381 , June 2008

Role of vasopressinergic V1 receptor agonists in the treatment of perioperative catecholamine-refractory arterial hypotension

  • Matthias Lange, MD (Research Fellow and Resident)

      Affiliations

    • Corresponding Author InformationCorresponding author. Department of Anaesthesiology and Intensive Care, University Hospital of Muenster, Albert-Schweitzer-Strasse 33, D–48149 Muenster, Germany. Tel.: +49 251 8347255; Fax: +49 251 8348667.
    • ,
  • Hugo Van Aken, MD, PhD, FRCA, FANZCA (Professor)
    • ,
  • Martin Westphal, MD, PhD (Professor in Anaesthesiology and Intensive Care)

References 

  1. Courneya CA, Korner PI. Neurohumoral mechanisms and the role of arterial baroreceptors in the reno-vascular response to haemorrhage in rabbits. The Journal of Physiology. 1991;437:393–407
  2. Oberg B. Overall cardiovascular regulation. Annual Review of Physiology. 1976;38:537–570
  3. Bertrand M, Godet G, Meersschaert K, et al. Should the angiotensin II antagonists be discontinued before surgery?. Anesthesia and Analgesia. 2001;92(1):26–30
  4. Colson P, Ryckwaert F, Coriat P. Renin angiotensin system antagonists and anesthesia. Anesthesia and Analgesia. 1999;89(5):1143–1155
  5. Miller ED, Ackerly JA, Peach MJ. Blood pressure support during general anesthesia in a renin-dependent state in the rat. Anesthesiology. 1978;48(6):404–408
  6. The CONSENSUS Trial Study Group . Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The New England Journal of Medicine. 1987;316(23):1429–1435
  7. Francis GS. ACE inhibition in cardiovascular disease. The New England Journal of Medicine. 2000;342(3):201–202
  8. Moser M. Angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists and calcium channel blocking agents: a review of potential benefits and possible adverse reactions. Journal of the American College of Cardiology. 1997;29(7):1414–1421
  9. Colson P, Saussine M, Seguin JR, et al. Hemodynamic effects of anesthesia in patients chronically treated with angiotensin-converting enzyme inhibitors. Anesthesia and Analgesia. 1992;74(6):805–808
  10. Kataja JH, Kaukinen S, Viinamaki OV, et al. Hemodynamic and hormonal changes in patients pretreated with captopril for surgery of the abdominal aorta. Journal of Cardiothoracic Anesthesia. 1989;3(4):425–432
  11. Oh YJ, Lee JH, Nam SB, et al. Effects of chronic angiotensin II receptor antagonist and angiotensin-converting enzyme inhibitor treatments on neurohormonal levels and haemodynamics during cardiopulmonary bypass. British Journal of Anaesthesia. 2006;97(6):792–798
  12. Schrier RW, Berl T, Anderson RJ. Osmotic and nonosmotic control of vasopressin release. American Journal of Physiology. 1979;236(4):F321–F332
  13. Holmes CL, Landry DW, Granton JT. Science review: vasopressin and the cardiovascular system part 1 – receptor physiology. Critical Care. 2003;7(6):427–434
  14. Braunwald E, Wagner HN. The pressor effect of the antidiuretic principle of the posterior pituitary in orthostatic hypotension. The Journal of Clinical Investigation. 1956;35(12):1412–1418
  15. Grollman A, Geiling EMK. The cardiovascular and metabolic reactions of man to the intramuscular injection of posterior pituitary liquid (pituirin), pitressin and pitocin. The Journal of Pharmacology and Experimental Therapeutics. 1932;46:447–460
  16. Cohn SM. Potential benefit of vasopressin in resuscitation of hemorrhagic shock. The Journal of Trauma. 2007;62(Suppl. 6):S56–S57
  17. Landry DW, Levin HR, Gallant EM, et al. Vasopressin pressor hypersensitivity in vasodilatory septic shock. Critical Care Medicine. 1997;25(8):1279–1282
  18. Schwartz J, Keil LC, Maselli J, et al. Role of vasopressin in blood pressure regulation during adrenal insufficiency. Endocrinology. 1983;112(1):234–238
  19. Freedman M, Kundig H, Leiman BC. The treatment of resistant hypotension with ornipressin. A case report. South African Medical Journal. 1985;67(1):29–31
  20. Boccara G, Ouattara A, Godet G, et al. Terlipressin versus norepinephrine to correct refractory arterial hypotension after general anesthesia in patients chronically treated with renin-angiotensin system inhibitors. Anesthesiology. 2003;98(6):1338–1344
  21. Brabant SM, Bertrand M, Eyraud D, et al. The hemodynamic effects of anesthetic induction in vascular surgical patients chronically treated with angiotensin II receptor antagonists. Anesthesia and Analgesia. 1999;89(6):1388–1392
  22. Brabant SM, Eyraud D, Bertrand M, et al. Refractory hypotension after induction of anesthesia in a patient chronically treated with angiotensin receptor antagonists. Anesthesia and Analgesia. 1999;89(4):887–888
  23. Eyraud D, Brabant S, Nathalie D, et al. Treatment of intraoperative refractory hypotension with terlipressin in patients chronically treated with an antagonist of the renin-angiotensin system. Anesthesia and Analgesia. 1999;88(5):980–984
  24. Meersschaert K, Brun L, Gourdin M, et al. Terlipressin-ephedrine versus ephedrine to treat hypotension at the induction of anesthesia in patients chronically treated with angiotensin converting-enzyme inhibitors: a prospective, randomized, double-blinded, crossover study. Anesthesia and Analgesia. 2002;94(4):835–840[table of contents]
  25. Morales DL, Garrido MJ, Madigan JD, et al. A double-blind randomized trial: prophylactic vasopressin reduces hypotension after cardiopulmonary bypass. The Annals of Thoracic Surgery. 2003;75(3):926–930
  26. Morelli A, Tritapepe L, Rocco M, et al. Terlipressin versus norepinephrine to counteract anesthesia-induced hypotension in patients treated with renin-angiotensin system inhibitors: effects on systemic and regional hemodynamics. Anesthesiology. 2005;102(1):12–19
  27. Vaquero Roncero LM, Julian Gonzalez R, Muriel Villoria C. Refractory hypotension during anesthesia in a patient treated with angiotensin receptor blockers. Revista Espanola de Anestesiologia y Reanimacion. 2004;51(6):338–341
  28. De Kock M, Laterre PF, Andruetto P, et al. Ornipressin (Por 8): an efficient alternative to counteract hypotension during combined general/epidural anesthesia. Anesthesia and Analgesia. 2000;90(6):1301–1307
  29. Peters J, Schlaghecke R, Thouet H, et al. Endogenous vasopressin supports blood pressure and prevents severe hypotension during epidural anesthesia in conscious dogs. Anesthesiology. 1990;73(4):694–702
  30. Argenziano M, Choudhri AF, Oz MC, et al. A prospective randomized trial of arginine vasopressin in the treatment of vasodilatory shock after left ventricular assist device placement. Circulation. 1997;96(Suppl. 9):II-286–II-290
  31. Dunser MW, Mayr AJ, Ulmer H, et al. Arginine vasopressin in advanced vasodilatory shock: a prospective, randomized, controlled study. Circulation. 2003;107(18):2313–2319
  32. Morales DL, Gregg D, Helman DN, et al. Arginine vasopressin in the treatment of 50 patients with postcardiotomy vasodilatory shock. The Annals of Thoracic Surgery. 2000;69(1):102–106
  33. Gold JA, Cullinane S, Chen J, et al. Vasopressin as an alternative to norepinephrine in the treatment of milrinone-induced hypotension. Critical Care Medicine. 2000;28(1):249–252
  34. Jeon Y, Ryu JH, Lim YJ, et al. Comparative hemodynamic effects of vasopressin and norepinephrine after milrinone-induced hypotension in off-pump coronary artery bypass surgical patients. European Journal of Cardio-thoracic Surgery: Official Journal of the European Association for Cardio-thoracic Surgery. 2006;29(6):952–956
  35. Hall JE, Coleman TG, Guyton AC. The renin-angiotensin system. Normal physiology and changes in older hypertensives. Journal of the American Geriatrics Society. 1989;37(8):801–813
  36. Licker M, Morel DR. Inhibitors of the renin angiotensin system: implications for the anaesthesiologist. Current Opinion in Anaesthesiology. 1998;11(3):321–326
  37. Fejes-Toth G, Brinck-Johnsen T, Naray-Fejes-Toth A. Cardiovascular and hormonal response to hemorrhage in conscious rats. American Journal of Physiology. 1988;254(5 Pt 2):H947–H953
  38. Schadt JC, Gaddis RR. Renin-angiotensin system and opioids during acute hemorrhage in conscious rabbits. American Journal of Physiology. 1990;258(2 Pt 2):R543–R551
  39. Coriat P, Richer C, Douraki T, et al. Influence of chronic angiotensin-converting enzyme inhibition on anesthetic induction. Anesthesiology. 1994;81(2):299–307
  40. Campbell DJ. The site of angiotensin production. Journal of Hypertension. 1985;3(3):199–207
  41. Oparil S, Haber E. The renin-angiotensin system. The New England Journal of Medicine. 1974;291(8):389–401
  42. Haber E, George C. Griffith lecture. The role of renin in normal and pathological cardiovascular homeostasis. Circulation. 1976;54(6):849–861
  43. Sancho J, Re R, Burton J, et al. The role of the renin-angiotensin-aldosterone system in cardiovascular homeostasis in normal human subjects. Circulation. 1976;53(3):400–405
  44. Ito N, Ohishi M, Yamamoto K, et al. Renin-angiotensin inhibition reverses advanced cardiac remodeling in aging spontaneously hypertensive rats. American Journal of Hypertension. 2007;20(7):792–799
  45. Lee S, Lee S, Sharma K. The pathogenesis of fibrosis and renal disease in scleroderma: recent insights from glomerulosclerosis. Current Rheumatology Reports. 2004;6(2):141–148
  46. Breckenridge A. Angiotensin converting enzyme inhibitors. British Medical Journal (Clinical Research Ed.). 1988;296(6622):618–620
  47. Wolny A, Clozel JP, Rein J, et al. Functional and biochemical analysis of angiotensin II-forming pathways in the human heart. Circulation Research. 1997;80(2):219–227
  48. Huang XR, Chen WY, Truong LD, et al. Chymase is upregulated in diabetic nephropathy: implications for an alternative pathway of angiotensin II-mediated diabetic renal and vascular disease. Journal of the American Society of Nephrology. 2003;14(7):1738–1747
  49. Roig E, Perez-Villa F, Morales M, et al. Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure. European Heart Journal. 2000;21(1):53–57
  50. Asmar R. Targeting effective blood pressure control with angiotensin receptor blockers. International Journal of Clinical Practice. 2006;60(3):315–320
  51. Burnier M. Angiotensin II type 1 receptor blockers. Circulation. 2001;103(6):904–912
  52. Hebert PR, Foody JM, Hennekens CH. The renin-angiotensin system: the role of inhibitors, blockers, and genetic polymorphisms in the treatment and prevention of heart failure. Current Vascular Pharmacology. 2003;1(1):33–39
  53. Unger T. Pharmacology of AT1-receptor blockers. Blood Pressure. Supplement. 2001;3:5–10
  54. Tuman KJ, McCarthy RJ, O'Connor CJ, et al. Angiotensin-converting enzyme inhibitors increase vasoconstrictor requirements after cardiopulmonary bypass. Anesthesia and Analgesia. 1995;80(3):473–479
  55. Licker M, Neidhart P, Lustenberger S, et al. Long-term angiotensin-converting enzyme inhibitor treatment attenuates adrenergic responsiveness without altering hemodynamic control in patients undergoing cardiac surgery. Anesthesiology. 1996;84(4):789–800
  56. Boldt J, Knothe C, Schindler F, et al. Isolated circulatory response to intravenous administration of the ACE inhibitor enalaprilat. British Journal of Clinical Pharmacology. 1994;37(4):341–346
  57. Boldt J, Menges T, Wollbruck M, et al. Continuous i.v. administration of the angiotensin-converting enzyme inhibitor enalaprilat in the critically ill: effects on regulators of circulatory homeostasis. Journal of Cardiovascular Pharmacology. 1995;25(3):416–423
  58. Mirenda JV, Grissom TE. Anesthetic implications of the renin-angiotensin system and angiotensin-converting enzyme inhibitors. Anesthesia and Analgesia. 1991;72(5):667–683
  59. Unger T, Gohlke P. Tissue renin-angiotensin systems in the heart and vasculature: possible involvement in the cardiovascular actions of converting enzyme inhibitors. The American Journal of Cardiology. 1990;65(19):31–101
  60. Waeber B, Nussberger J, Juillerat L, et al. Angiotensin converting enzyme inhibition: discrepancy between antihypertensive effect and suppression of enzyme activity. Journal of Cardiovascular Pharmacology. 1989;14(Suppl. 4):S53–S59
  61. Ullman JE, Hjelmqvist H, Rundgren M, et al. Hemodynamic effects of vasopressin antagonism and angiotensin I converting enzyme inhibition during halothane anesthesia in sheep. Acta Anaesthesiologica Scandinavica. 1992;36(2):132–137
  62. Carp H, Vadhera R, Jayaram A, et al. Endogenous vasopressin and renin-angiotensin systems support blood pressure after epidural block in humans. Anesthesiology. 1994;80(5):1000–1007[discussion 1027A–1028A]
  63. Jochberger S, Wenzel V, Dunser MW. Arginine vasopressin as a rescue vasopressor agent in the operating room. Current Opinion in Anaesthesiology. 2005;18(4):396–404
  64. Pesaturo AB, Jennings HR, Voils SA. Terlipressin: vasopressin analog and novel drug for septic shock. The Annals of Pharmacotherapy. 2006;40(12):2170–2177
  65. Laszlo FA, Laszlo F, De Wied D. Pharmacology and clinical perspectives of vasopressin antagonists. Pharmacological Reviews. 1991;43(1):73–108
  66. Medel J, Boccara G, Van de Steen E, et al. Terlipressin for treating intraoperative hypotension: can it unmask myocardial ischemia?. Anesthesia and Analgesia. 2001;93(1):53–55

PII: S1521-6896(08)00024-4

doi: 10.1016/j.bpa.2008.02.010

Best Practice & Research Clinical Anaesthesiology
Volume 22, Issue 2 , Pages 369-381 , June 2008

Article Tools

* Image Usage & Resolution